Whales with a lot of money to spend have taken a noticeably bearish stance on Axsome Therapeutics.
Looking at options history for Axsome Therapeutics AXSM we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $2,365,912 and 5, calls, for a total amount of $327,807.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $110.0 for Axsome Therapeutics over the recent three months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Axsome Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Axsome Therapeutics's whale trades within a strike price range from $75.0 to $110.0 in the last 30 days.
Axsome Therapeutics 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AXSM | PUT | TRADE | BULLISH | 01/17/25 | $15.0 | $11.7 | $12.05 | $92.50 | $1.6M | 1.7K | 1.3K |
| AXSM | PUT | SWEEP | BEARISH | 01/17/25 | $6.0 | $4.9 | $6.0 | $80.00 | $245.4K | 3.0K | 1.6K |
| AXSM | PUT | SWEEP | BEARISH | 01/17/25 | $6.4 | $6.1 | $6.4 | $80.00 | $190.6K | 3.0K | 184 |
| AXSM | CALL | TRADE | BEARISH | 01/16/26 | $11.5 | $9.9 | $9.9 | $110.00 | $122.7K | 16 | 250 |
| AXSM | CALL | TRADE | BULLISH | 01/16/26 | $9.9 | $7.2 | $9.2 | $110.00 | $115.0K | 16 | 125 |
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
After a thorough review of the options trading surrounding Axsome Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Axsome Therapeutics's Current Market Status
- Currently trading with a volume of 2,190,797, the AXSM's price is down by -9.18%, now at $78.75.
- RSI readings suggest the stock is currently may be oversold.
- Anticipated earnings release is in 50 days.
What The Experts Say On Axsome Therapeutics
In the last month, 2 experts released ratings on this stock with an average target price of $125.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $121. * In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $130.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Axsome Therapeutics with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
